Severe apoptotic enteropathy caused by methotrexate treatment for rheumatoid arthritis.

[1]  P. Abraham,et al.  Mitochondrial dysfunction and respiratory chain defects in a rodent model of methotrexate-induced enteritis , 2014, Human & experimental toxicology.

[2]  J. Macdonald,et al.  Methotrexate for maintenance of remission in Crohn's disease. , 2014, The Cochrane database of systematic reviews.

[3]  M. Schiff,et al.  Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration , 2014, Annals of the rheumatic diseases.

[4]  G. Rogler,et al.  Apoptotic enteropathy caused by antimetabolites and TNF-α antagonists , 2014, Journal of Clinical Pathology.

[5]  T. Tsukada,et al.  Life-Threatening Gastrointestinal Mucosal Necrosis during Methotrexate Treatment for Rheumatoid Arthritis , 2013, Case Reports in Gastroenterology.

[6]  D. Bentué-Ferrer,et al.  Suivi thérapeutique pharmacologique du méthotrexate à faible dose dans les maladies inflammatoires , 2011 .

[7]  Rong W. Zablocki,et al.  Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. , 2010, Rheumatology.

[8]  M. Genevay,et al.  Atteintes médicamenteuses du tractus gastro-intestinal: une revue clinico-pathologique , 2010 .

[9]  Cheng Cheng,et al.  Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  U Pichlmeier,et al.  Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. , 2008, Arthritis and rheumatism.

[11]  M. A. van de Laar,et al.  Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[12]  Y. Masubuchi,et al.  Evaluation of damaged small intestine of mouse following methotrexate administration , 1997, Cancer Chemotherapy and Pharmacology.

[13]  F. Lee.  Importance of apoptosis in the histopathology of drug related lesions in the large intestine. , 1993, Journal of clinical pathology.

[14]  B Bégaud,et al.  Imputabilité des effets inattendus ou toxiques des médicaments: actualisation de la méthode utilisée en France , 1985 .